CHAPEL HILL, N.C., February 3, 2026 — SonoVascular, Inc., a clinical-stage medical device company focused on improving treatment for venous thromboembolism (VTE), has completed the first close of its $6 million Series A preferred stock financing. Led by Harbright Ventures, the funding will accelerate clinical development of the company’s investigational SonoThrombectomy™ System, an ultrasound-facilitated thrombectomy platform designed to safely and effectively remove blood clots in deep vein thrombosis (DVT) and pulmonary embolism (PE).
Science Significance
At the scientific core of SonoVascular’s innovation is a microbubble-mediated cavitation mechanism that uses targeted ultrasound energy to mechanically disrupt thrombus while minimizing damage to surrounding tissue. Unlike traditional mechanical thrombectomy systems that can cause blood loss, endothelial injury, or venous valve damage, the SonoThrombectomy™ System is designed as a single-session, catheter-based procedure that maximizes clot reduction without vascular trauma. In a First-In-Human (FIH) feasibility study conducted in South America, the system achieved a 100% Marder score clot reduction in all ten treated patients, as independently adjudicated by a core laboratory. Importantly, follow-up at 30 days and six months showed sustained improvements in post-thrombotic syndrome severity, venous clinical scores, and pain ratings, suggesting durable clinical benefit.
Regulatory Significance
From a regulatory standpoint, SonoVascular’s progress highlights the pathway for novel intravascular ultrasound-based devices addressing unmet needs in VTE care. The company plans to use the Series A proceeds to secure FDA approval for a U.S.-based peripheral venous pivotal study, a critical milestone toward eventual market clearance. In parallel, SonoVascular intends to initiate a FIH study for pulmonary embolism, expanding the clinical scope of the platform. The device remains investigational and not yet FDA-approved, but the absence of device-related serious adverse events in early human use strengthens the regulatory foundation for continued clinical evaluation under Good Clinical Practice (GCP) standards.
Business Significance
Advertisement
Strategically, the financing marks a key inflection point for SonoVascular as it transitions from early feasibility into late-stage clinical validation. Harbright Ventures’ leadership in the round and the addition of its founding partner, Robert Ross, to SonoVascular’s board bring both capital and strategic expertise. Investors cited the company’s ability to address the long-standing “trade-off problem” in DVT treatment—achieving high clot clearance without bleeding or vessel damage—as a differentiating factor. By potentially reducing intensive care utilization and repeat procedures, the SonoThrombectomy™ System may offer hospitals a cost-effective alternative to existing therapies, supporting a compelling health economics narrative alongside clinical performance.
Patients’ Significance
For patients, particularly those suffering from DVT and PE, the technology addresses a major clinical burden. VTE affects up to 900,000 individuals annually in the United States, with a substantial proportion developing post-thrombotic syndrome, a chronic and sometimes disabling condition. Current treatment options often involve compromises between efficacy and safety. Early clinical experience with SonoThrombectomy™ suggests the potential for complete clot removal without blood loss, preservation of venous valves, and meaningful symptom relief over time. If validated in larger trials, this approach could significantly improve long-term mobility, quality of life, and survival, especially for patients at high risk of complications.
Policy Significance
At the policy level, SonoVascular’s advancement reflects broader healthcare priorities focused on reducing complication rates, hospital length of stay, and downstream costs associated with thromboembolic disease. Technologies that enable effective, minimally invasive, and resource-efficient interventions align with payer and health system goals of value-based care. As policymakers and regulators continue to emphasize innovation that improves outcomes while controlling costs, successful development of safer thrombectomy solutions could influence future clinical guidelines and reimbursement frameworks for VTE management.
The successful first close of SonoVascular’s Series A financing underscores growing confidence in ultrasound-enabled thrombectomy as a next-generation approach to VTE treatment. Backed by encouraging first-in-human results and a clear regulatory and clinical roadmap, the company is positioned to advance its SonoThrombectomy™ System toward pivotal studies and broader indications. As development progresses, SonoVascular’s technology may help redefine how clinicians manage blood clots—offering a path toward safer procedures, better patient outcomes, and more sustainable healthcare delivery.
Source: SonoVascular, Inc. press release
